GlassScriptPhysician profile
Matthew Blaszka
NPI 1962632083
$4,382.46
in general payments reported to CMS, 2019-2025
40 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $309 · 2021: $397 · 2022: $305 · 2023: $680 · 2024: $800 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $431.45 | 2019-2025 | Entyvio, Trintellix, Eohilia |
| Abbvie INC. | $403.12 | 2019-2025 | Rinvoq, Linzess, Creon |
| Ardelyx, INC. | $261.14 | 2022-2025 | Ibsrela |
| Olympus America INC. | $236.63 | 2019 | |
| Celgene Corporation | $220.40 | 2021-2024 | Zeposia |
| Glaxosmithkline, LLC. | $215.20 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $196.29 | 2022-2025 | Xywav |
| Novo Nordisk INC | $182.70 | 2021-2025 | Wegovy |
| Redhill Biopharma INC. | $177.86 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Lilly USA, LLC | $171.42 | 2020-2024 | Omvoh |
| Janssen Biotech, INC. | $164.14 | 2024-2025 | Tremfya, Simponi, Stelara |
| Phathom Pharmaceuticals, INC. | $152.94 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.06 | 2019-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $142.85 | 2025 | Rezdiffra |
| Pfizer INC. | $132.48 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Blaszka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.